ASBP Aspire-Lakewood Holdings, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1847345 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY41.6%
TTM EPS YoY201.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin-25.0%
Operating margin-7,494.8%
Net margin-11,314.1%
FCF margin—
EBITDA margin—
Returns
ROE-1,032.1%
ROA-152.1%
ROIC (approx.)—
Asset turnover0.01x
Leverage & solvency
Liabilities / assets13.2%
Debt / equity0.00x
Current ratio7.99x
Interest coverage-0.79x
Cash quality & payout
Operating cash flow / net income0.65x
Accruals ratio-53.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $6,202 | — | — | — |
| Cost of revenue | $6,318 | — | — | — |
| Gross profit | -$116 | — | — | — |
| R&D expense | $923,914 | $144,356 | — | — |
| SG&A expense | $17.64M | $940,421 | $1.34M | $976,345 |
| Operating income | -$19.35M | -$1.21M | — | — |
| Interest expense | $8.53M | $97,988 | $8,966 | — |
| Pretax income | -$24.48M | -$1.31M | — | — |
| Income tax | — | $1,013 | — | — |
| Net income | -$24.48M | -$1.31M | $4.46M | $3.34M |
| EPS (diluted) | -16.38 | -1.90 | — | — |
| Weighted avg. shares (diluted) | 1.49M | 689,913 | — | — |
| Balance sheet | ||||
| Cash & equivalents | $1.00M | $3,633 | $11,174 | $497,259 |
| Inventory | $253,160 | — | — | — |
| Current assets | $1.31M | $147,989 | $81,223 | $1.10M |
| Total assets | $1.31M | $147,989 | $19.98M | $300.18M |
| Current liabilities | $7.59M | $1.69M | $403,328 | $303,323 |
| Total liabilities | $7.69M | $1.69M | $403,328 | $11.12M |
| Shareholders' equity | -$6.38M | -$1.54M | -$487,861 | -$9.94M |
| Shares outstanding | 117,780 | 690,044 | — | — |
| Cash flow statement | ||||
| Operating cash flow | -$4.92M | -$265,186 | -$653,107 | -$1.41M |
| Investing cash flow | — | $13.78M | $284.92M | -$294.69M |
| Financing cash flow | $5.92M | $257,645 | -$284.76M | $296.59M |
| Stock-based compensation | $14.13M | $0 | — | — |
| Share buybacks | — | $13.78M | $284.92M | — |
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.